Gandara DR - Search Results

1

Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, Blanke CD, LeBlanc ML, Kelly K, Gray JE, Redman MW. Vaidya R, et al. Among authors: gandara dr. JCO Precis Oncol. 2023 Sep;7:e2300218. doi: 10.1200/PO.23.00218. JCO Precis Oncol. 2023. PMID: 37677122

2

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen.

Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW. Gandara DR, et al. J Natl Cancer Inst. 1989 May 10;81(10):790-4. doi: 10.1093/jnci/81.10.790. J Natl Cancer Inst. 1989. PMID: 2541260

3

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.

Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, et al. Gandara DR, et al. J Clin Oncol. 1993 May;11(5):873-8. doi: 10.1200/JCO.1993.11.5.873. J Clin Oncol. 1993. PMID: 8387576 Clinical Trial.

4

Promising new agents in the treatment of non-small cell lung cancer.

Edelman MJ, Gandara DR. Edelman MJ, et al. Among authors: gandara dr. Cancer Chemother Pharmacol. 1996;37(5):385-93. doi: 10.1007/s002800050402. Cancer Chemother Pharmacol. 1996. PMID: 8599859 Review.

5

Multimodality therapy in stage III non-small cell lung cancer.

Edelman MJ, Gandara DR, Roach M 3rd, Benfield JR. Edelman MJ, et al. Among authors: gandara dr. Ann Thorac Surg. 1996 May;61(5):1564-72. doi: 10.1016/0003-4975(96)00044-6. Ann Thorac Surg. 1996. PMID: 8633990 Review.

6

Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.

Lau DH, Ryu JK, Gandara DR. Lau DH, et al. Among authors: gandara dr. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-110-S12-112. Semin Oncol. 1997. PMID: 9331133 Clinical Trial.

7

Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.

Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Gandara DR, et al. Cancer Chemother Pharmacol. 1997;41(1):75-8. doi: 10.1007/s002800050710. Cancer Chemother Pharmacol. 1997. PMID: 9443617 Clinical Trial.

8

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.

Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Gandara DR, et al. Support Care Cancer. 1998 May;6(3):237-43. doi: 10.1007/s005200050160. Support Care Cancer. 1998. PMID: 9629876 Review.

9

Small cell lung cancer: current status of new chemotherapeutic agents.

Edelman MJ, Gandara DR. Edelman MJ, et al. Among authors: gandara dr. Crit Rev Oncol Hematol. 1998 Apr;27(3):211-20. doi: 10.1016/s1040-8428(98)00002-x. Crit Rev Oncol Hematol. 1998. PMID: 9649933 Review. No abstract available.

10

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Wozniak AJ, et al. Among authors: gandara dr. J Clin Oncol. 1998 Jul;16(7):2459-65. doi: 10.1200/JCO.1998.16.7.2459. J Clin Oncol. 1998. PMID: 9667264 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

410 results

Search Page